Pasar al contenido principal

Biofísica e inmunología aplicadas a la investigacion biomédica

RYC2021-031256-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Desarrollar, Atraer y Retener Talento
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE SEVILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Modulation of the Immune Response to Allergies Using Alternative Functional Foods

  • López-Enríquez, Soledad
  • Múnera-Rodríguez, Ana M.
  • Leiva-Castro, Camila
  • Sobrino Castelló, Francisco
  • Palomares, Francisca
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Modulation of the allergic immune response through alternative therapies is a field of study that aims to address allergic reactions differently from traditional approaches. These therapies encompass the utilization of natural functional foods, which have been observed to exert an influence on the immune response, thus mitigating the severity of allergies. Indeed, some studies suggest that the incorporation of these nutraceuticals can regulate immune function, leading to a reduction in histamine release and subsequent alleviation of allergic symptoms. Moreover, certain herbs and dietary supplements, such as curcumin, are believed to possess anti-inflammatory properties, which may serve to moderate allergic responses. Although the results remain somewhat mixed and require further research, these alternative therapies exhibit the potential to impact the allergic immune response, thereby providing complementary options to conventional treatments. Therefore, in this review, we aim to provide an updated account of functional foods capable of modulating the immune response to allergies. In that sense, the review delves into functional foods sourced from plants (phytochemicals), animals, and marine algae. Emphasis is placed on their potential application in the treatment of allergic disorders. It also provides an overview of how these foods can be effectively utilized as functional foods. Additionally, it explores the molecular mechanisms and scientific validity of various bioactive natural compounds in the management of allergies., This work was supported by grants by “VII Plan Propio de Investigación y Transferencia” from the University of Seville (Project-202200000421 and Project-2023/00000482), and by the Ministry of Science and Innovation through research Ramon y Cajal program (RYC2021-031256-I) from Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dendritic Cells as a Therapeutic Strategy in Acute Myeloid Leukemia: Vaccines

  • Palomares, Francisca
  • Pina, Alejandra
  • Dakhaoui, Hala
  • Leiva-Castro, Camila
  • Múnera-Rodríguez, Ana M.
  • Cejudo-Guillén, Marta
  • Granados, Beatriz
  • Alba, Gonzalo
  • Santa-María, Consuelo
  • Sobrino Castelló, Francisco
  • López-Enríquez, Soledad
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Dendritic cells (DCs) serve as professional antigen-presenting cells (APC) bridging innate and adaptive immunity, playing an essential role in triggering specific cellular and humoral responses against tumor and infectious antigens. Consequently, various DC-based antitumor therapeutic strategies have been developed, particularly vaccines, and have been intensively investigated specifically in the context of acute myeloid leukemia (AML). This hematological malignancy mainly affects the elderly population (those aged over 65), which usually presents a high rate of therapeutic failure and an unfavorable prognosis. In this review, we examine the current state of development and progress of vaccines in AML. The findings evidence the possible administration of DC-based vaccines as an adjuvant treatment in AML following initial therapy. Furthermore, the therapy demonstrates promising outcomes in preventing or delaying tumor relapse and exhibits synergistic effects when combined with other treatments during relapses or disease progression. On the other hand, the remarkable success observed with RNA vaccines for COVID-19, delivered in lipid nanoparticles, has revealed the efficacy and effectiveness of these types of vectors, prompting further exploration and their potential application in AML, as well as other neoplasms, loading them with tumor RNA., This work was supported by grants by “VII Plan Propio de Investigación y Transferencia” from the University of Seville (Project-202200000421 and Project-2023/00000482), and by the Ministry of Science and Innovation trough research Ramon y Cajal program (RYC2021-031256-I) from Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Sulforaphane-mediated immune regulation through inhibition of NF-kB and MAPK signaling pathways in human dendritic cells

  • Múnera-Rodríguez, Ana M.
  • Leiva-Castro, Camila
  • Sobrino, Francisco
  • López-Enríquez, Soledad
  • Palomares, Francisca
Inflammation and immune responses are intricately intertwined processes crucial for maintaining homeostasis and combating against pathogens. These processes involve complex signaling pathways, notably the Nuclear Factor kappa-light-chain-enhancer of activated B-cells (NF-κB) and Mitogen-Activated Protein Kinase (MAPK) pathways, which play crucial roles. Sulforaphane (SFN), a nutraceutic, has emerged as a potential regulator of NF-κB and MAPK signaling pathways, exhibiting anti-inflammatory properties. However, limited knowledge exists regarding SFN's effects on immune cell modulation. This study aimed to assess the immunomodulatory capacity of SFN pretreatment in human dendritic cells (DCs), followed by exposure to a chronic inflammatory environment induced by lipopolysaccharide. SFN pretreatment was found to inhibit the NF-κB and MAPK signaling pathways, resulting in phenotypic changes in DCs characterized by a slight reduction in the expression of surface markers, as well as a decrease of TNF-α/IL-10 ratio. Additionally, SFN pretreatment enhanced the proliferation of Treg-cells and promoted the production of IL-10 by B-cells before exposure to the chronic inflammatory environment. Furthermore, these changes in DCs were found to be influenced by the inhibition of NF-κB and MAPK pathways (specifically p38 MAPK and JNK), suggesting that these pathways may play a role in the regulation of the differentiation of adaptive immune responses (proliferation of T- and IL-10-producing regulatory-cells), prior to SFN pretreatment. Our findings suggest that SFN pretreatment may induce a regulatory response by inhibiting NF-κB and MAPK signaling pathways in an inflammatory environment. SFN could be considered a promising strategy for utilizing functional foods to protect against inflammation and develop immunoregulatory interventions., This work was supported by grants by “VII Plan Propio de Investigación y Transferencia” from the University of Seville (Project-202200000421 and Project-2023/00000482), by the Ministry of Science and Innovation through research Ramon y Cajal program (RYC2021–031256-I) from Spain and Asociación Universitaria Iberoamericana de Postgrado scholarship for the Medical Research: Clinical and Experimental Master., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tissue-specific early and late activated lymphocytes immunophenotype in chronic rhinosinusitis with nasal polyps

  • López-Enríquez, Soledad
  • Porras-González, Cristina
  • Moreno-Luna, Ramón
  • Palomares, Francisca
  • Muñoz-Bravo, José Luis
  • Alba, Gonzalo
  • Santa-María, Consuelo
  • Maza-Solano, Juan
  • Martín-Jiménez, Daniel Iván
  • Pérez-Pérez, Antonio
  • Moreno-Luna, Rafael
  • Sánchez-Margalet, Víctor
  • Sánchez-Gómez, Serafín
T-cell activation in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) is enriched by late cytotoxic T cells. The proportion of early and intermediate activated cytotoxic T cells decreases in nasal polyps of patients with CRSwNP. Our results identify late activated cytotoxic T cells as potential biomarkers or therapeutic targets for patients with CRSwNP., Consejería de Salud y Familias, Junta de Andalucía, Grant/Award Numbers:PI-0212-2017, PIGE-0367-2019,RH-0048-2021; Consejería deTransformación Económica, Industria,Conocimiento y Universidades, Junta de Andalucía, Grant/Award Number:PAIDIDOCTOR-2021; Ministerio de Ciencia e Innovación-Agencia Estatal deInvestigación, Grant/Award Numbers:Grant MCIN/AEI/10, 13039/501100011033,RYC2021-031256-I. We thank the Anatomical Pathology Unit (especially to Maria Jose Rios Moreno) and the Biobank facility of the Virgen Macarena University Hospital of Seville (Nodo Biobanco Del Sistema Sanitario Público de Andalucía) integrated in the Spanish National biobanks Network (PT20/00069) funded by FEDER and ISCIII funds., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Monovalent glycoconjugates of sulforaphane prevent inflammation induced by lipopolysaccharide in human dendritic cells by inhibiting NF-ĸB signalling pathway

  • Leiva-Castro, Camila
  • Múnera-Rodríguez, Ana M.
  • Martínez-Bailén, Macarena
  • Carmona, Ana T.
  • López-Enríquez, Soledad
  • Palomares, Francisca
[Background and Purpose] Sulforaphane (SFN) has notable health benefits but faces challenges due to its poor solubility and delivery. This study investigates SFN-glycoconjugates effects on lipopolysaccharide (LPS)-induced inflammation in dendritic cells (DCs). With the aiming to enhance their therapeutic potential against inflammatory diseases. Novel monovalent SFN-glycoconjugates with mannose (Man) and fucose (0Fuc) were developed and tested for their anti-inflammatory and immune-modulatory properties in DCs from healthy donors under chronic LPS exposure., [Experimental Approach] By leveraging therapeutic strategies, SFN-glycoconjugates significantly improved the solubility and bioavailability of SFN, thereby overcoming the limitations of traditional delivery methods. Monocyte-derived DCs were treated with SFN-glycoconjugates and subsequently exposed to a chronic inflammatory environment induced by LPS., [Key Results] Our results showed that SFN-glycoconjugates enhance effectiveness in suppressing inflammation by targeting the p65 NF-κB pathway, without affecting MAPK signalling. SFN-glycoconjugates induce a tolerogenic immune response, characterized by increased IL-10 production and enhanced regulatory T- and B-cell proliferation. These effects surpass those of p65 NF-κB inhibition alone, highlighting a distinct and potent regulatory mechanism independent of MAPK pathways., [Conclusion and Implications] The integration of food therapeutic strategies not only enhances the stability and delivery of bioactive compounds but also broadens their potential applications in functional foods and therapeutic approaches. In particular, SFN-glycoconjugates represent a promising option as biologically active compounds for inflammatory diseases, offering enhanced anti-inflammatory and immunomodulatory effects through optimized delivery systems and the activation of specific molecular pathways., This work was supported by the Ministerio de Ciencia e Innovación (Grant PID2020-116460RB-100 funded by MCIN/AEI/10.13039/50110001103, Grant PID2023-147334OB-I00 funded by MICIU/AEI/10.13039/501100011033 and, as appropriate, by ‘ERDF A way of making Europe’, by ‘ERDF/EU’, by the ‘European Union’ and by Ramon y Cajal Program [RYC2021-031256-I] funded by MICIU/AEI/10.13039/501100011033 and, as appropriate, by ‘ESF Investing in your future’, by ‘ESF+’ or by ‘European Union NextGenerationEU/PRTR’), by the ‘VII Plan Propio de Investigación y Transferencia’ from the University of Seville (Project 202200000421 and Project 2023/00000482) and by Asociación Universitaria Iberoamericana de Postgrado scholarship for the Medical Research: Clinical and Experimental Master. We also thank CITIUS Universidad de Sevilla (MS and NMR services, including the flow cytometry services) and Edijs Jansons for technical assistance., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Autophagy in Obesity and Type 2 Diabetes: Beyond the Protective Paradigm

  • Angarita-Plánchez, María Elena
  • Sánchez-Rodríguez, Paula
  • Múnera-Rodríguez, Ana M.
  • Leiva-Castro, Camila
  • Benítez-Márquez, Juan Manuel
  • Reina-Pérez, Icíar
  • Palomares, Francisca
  • López-Enríquez, Soledad
[Purpose of Review] This review examines the current evidence on autophagy dysregulation in obesity and type 2 diabetes mellitus (T2DM), with particular emphasis on its tissue-specific nature and implications for clinical translation., [Recent findings] Recent human and preclinical evidence indicates that autophagic alterations in metabolic disease are not uniformly suppressed but vary according to tissue type and disease stage. In adipose tissue, liver, skeletal muscle, pancreatic β cells, and immune cells, dysregulated mTORC1-AMPK signaling, defective mitophagy, and impaired lysosomal function contribute to insulin resistance, ectopic lipid accumulation, and metaflammation. However, most human studies rely on static markers such as LC3, p62, and Beclin-1, which do not reliably reflect dynamic autophagic flux. Recent advances, including organelle-specific biomarkers, ex vivo functional assays, and circulating exosomal cargo, offer new translational opportunities, although standardization remains limited., [Summary] Autophagy in metabolic disease represents a context-dependent maladaptation rather than a uniformly protective pathway. Future progress will depend on harmonized biomarker panels, functional assessment of autophagic flux in humans, and integration with metabolic phenotyping to enable precision-based therapeutic strategies., Funding for open access publishing: Universidad de Sevilla/CBUA. This work was supported by the Instituto de Salud Carlos III (ISCIII) (Grant PI25/00574), funded by MCIN/ISCIII/https://doi.org/10.13039/501100004587 and co-funded by the European Union, and by the Ministerio de Ciencia e Innovación (Grant PID2023-147334OB-I00 funded by MICIU/AEI/https://doi.org/10.13039/501100011033 and, as appropriate, by ‘ERDF A way of making Europe’, by ‘ERDF/EU’, by the ‘European Union’, and by Ramon y Cajal program (RYC2021-031256-I) funded by MICIU/AEI/https://doi.org/10.13039/501100011033 and, as appropriate, by ‘ESF Investing in your future’, by ‘ESF + ’ or by ‘European Union NextGenerationEU/PRTR’), and by the ‘VII Plan Propio de Investigación y Transferencia’ from the University of Seville (Project-2023/00000482 and Project-2024/00000357), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Role of Autophagy in Inflammatory Diseases: Challenges and Therapeutic Potential

  • Múnera-Rodríguez, Ana M
  • Leiva-Castro, Camila
  • Reina-Pérez, Icíar
  • Benítez-Márquez, Juan Manuel
  • Palomares, Francisca
  • López-Enríquez, Soledad
Autophagy is a crucial cellular process involved in the degradation of cytoplasmic components through lysosomal machinery. It is essential for maintaining cellular homeostasis and responding to various stressors. Autophagy has emerged as a key regulator of immune responses, particularly in the context of chronic inflammatory diseases, such as inflammatory bowel diseases and cancer. Increasing evidence highlights its dual role in both exacerbating and controlling inflammation, depending on the disease context. This review critically examines the molecular mechanisms of autophagy, its regulation within immune cells, and its complex involvement in chronic inflammation. We explore how dysregulated autophagic processes contribute to disease pathogenesis, with particular focus on inflammatory bowel disease and how these conditions increase cancer risk. Furthermore, we discuss the potential of autophagy modulation as a therapeutic strategy for these diseases. Current therapeutic approaches targeting autophagy are reviewed, alongside emerging strategies and their clinical implications. This comprehensive analysis underscores the importance of understanding the multifaceted roles of autophagy in immune regulation, with the aim of advancing therapeutic interventions for inflammatory and cancer-related conditions., [Lay Summary] Autophagy critically regulates immune responses and inflammation. This review emphasizes its dual role in inflammatory bowel diseases, highlighting how dysregulated autophagy contributes to inflammatory bowel disease pathogenesis and cancer risk. Autophagy-targeting therapies offer promising strategies for treating chronic inflammatory disorders., This work was supported by grants by “VII Plan Propio de Investigación y Transferencia” from the University of Seville (Project-202200000421 and Project-2023/00000482), and by the Ministry of Science and Innovation through research Ramón y Cajal program (RYC2021-031256-I) from Spain., Peer reviewed